KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Capital Expenditures (2016 - 2025)

West Pharmaceutical Services' Capital Expenditures history spans 17 years, with the latest figure at $76.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 134.73% year-over-year to $76.1 million; the TTM value through Dec 2025 reached $285.9 million, up 439.43%, while the annual FY2025 figure was $285.9 million, 439.43% up from the prior year.
  • Capital Expenditures for Q4 2025 was $76.1 million at West Pharmaceutical Services, up from $63.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $230.5 million in Q3 2024 and bottomed at -$219.1 million in Q4 2024.
  • The 5-year median for Capital Expenditures is $66.0 million (2022), against an average of $33.9 million.
  • The largest annual shift saw Capital Expenditures plummeted 304.58% in 2022 before it soared 253.47% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $76.5 million in 2021, then tumbled by 304.58% to -$156.5 million in 2022, then dropped by 27.8% to -$200.0 million in 2023, then dropped by 9.55% to -$219.1 million in 2024, then skyrocketed by 134.73% to $76.1 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Capital Expenditures are $76.1 million (Q4 2025), $63.3 million (Q3 2025), and $75.2 million (Q2 2025).